latest news releases from the newsroom
VuBotics Announces Election of Marc Owensby to Board of Directors
ATLANTA, Aug. 22, 2007 (PRIME NEWSWIRE) -- VuBotics, Inc. (OTCBB:VBTC), developer of VuIT(tm), the global leader in small screen reading technology, today announced the election of Marc Owensby to its board of directors. Mr. Owensby will join the company's chairman and CEO, Philip Lundquist, as well as Robert Eramian and Ronan Harris, increasing the board to 4 members. Mr. Owensby brings extensive international mobile telecommunications industry expertise and emerging growth company experience.
Pride International, Inc.
Pride International, Inc. Acquires Remaining Interest in Angolan Joint Venture
HOUSTON, Aug. 22, 2007 (PRIME NEWSWIRE) -- Pride International, Inc. (NYSE:PDE) today announced that it has acquired the remaining nine percent interest in its Angolan joint venture company from a subsidiary of Sonangol, the national oil company of Angola. The joint venture owns the two deepwater drillships Pride Africa and Pride Angola and the 300 ft. independent-leg jackup rig Pride Cabinda, and holds management agreements for the deepwater platform rigs Kizomba A and Kizomba B. The acquisition increases Pride's ownership in the three mobile offshore drilling units and the two management agreements, along with related working capital, to 100 percent. Cash consideration in the transaction of $45 million was paid with cash on hand and borrowings under the company's revolving credit facility.
Talon Therapeutics, Inc.
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) in second relapse or who have failed two lines of prior therapy. Earlier this year, Marqibo was also granted Orphan Drug Designation by the FDA for the treatment of adult ALL.